TrialThe Lancet. Child & adolescent health2018

Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.

Pedro A de Alarcon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.